A Novel Mismatched PCR-Restriction Fragment Length Polymorphism Assay for Rapid Detection of gyrA and parC Mutations Associated With Fluoroquinolone Resistance in Acinetobacter baumannii
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: Mutations in the quinolone resistance-determining regions (QRDRs) of Acinetobacter baumannii DNA gyrase (gyrA) and topoisomerase IV (parC) are linked to fluoroquinolone (FQ) resistance. We developed a mismatched PCR-restriction fragment length polymorphism (RFLP) assay to detect mutations in the gyrA and parC QRDRs associated with FQ resistance in A. baumannii. Methods: Based on the conserved sequences of A. baumannii gyrA and parC, two primer sets were designed for mismatched PCR-RFLP to detect mutations in gyrA (codons 83 and 87) and parC (codons 80 and 84) by introducing an artificial restriction enzyme cleavage site into the PCR products. This assay was evaluated using 58 A. baumannii strains and 37 other Acinetobacter strains that have been identified by RNA polymerase β-subunit gene sequence analysis. Results: PCR amplification of gyrA and parC was successful for all A. baumannii strains. In 11 FQ -susceptible strains, the gyrA and parC PCR products were digested by the selected restriction enzymes at the site containing gyrA (codons 83 and 87) and parC (codons 80 and 84). PCR products from 47 FQ-resistant strains containing mutations in gyrA and parC were not digested by the restriction enzymes at the site containing the mutation. As for the non-baumannii Acinetobacter strains, although amplification products for gyrA were obtained for 28 strains, no parC amplification product was obtained for any strain. Conclusions: This assay specifically amplified gyrA and parC from A. baumannii and detected A. baumannii gyrA and parC mutations with FQ resistance.
Abstract
Background: Mutations in the quinolone resistance-determining regions (QRDRs) of Acinetobacter baumannii DNA gyrase (gyrA) and topoisomerase IV (parC) are linked to fluoroquinolone (FQ) resistance. We developed a mismatched PCR-restriction fragment length polymorphism (RFLP) assay to detect mutations in the gyrA and parC QRDRs associated with FQ resistance in A. baumannii. Methods: Based on the conserved sequences of A. baumannii gyrA and parC, two primer sets were designed for mismatched PCR-RFLP to detect mutations in gyrA (codons 83 and 87) and parC (codons 80 and 84) by introducing an artificial restriction enzyme cleavage site into the PCR products. This assay was evaluated using 58 A. baumannii strains and 37 other Acinetobacter strains that have been identified by RNA polymerase β-subunit gene sequence analysis. Results: PCR amplification of gyrA and parC was successful for all A. baumannii strains. In 11 FQ -susceptible strains, the gyrA and parC PCR products were digested by the selected restriction enzymes at the site containing gyrA (codons 83 and 87) and parC (codons 80 and 84). PCR products from 47 FQ-resistant strains containing mutations in gyrA and parC were not digested by the restriction enzymes at the site containing the mutation. As for the non-baumannii Acinetobacter strains, although amplification products for gyrA were obtained for 28 strains, no parC amplification product was obtained for any strain. Conclusions: This assay specifically amplified gyrA and parC from A. baumannii and detected A. baumannii gyrA and parC mutations with FQ resistance.
참고문헌 (23)
- Hooper DC, "Clinical applications of quinolones", Biochim Biophys Acta, 1400, pp.45~61 (1998)
- 김의석, "Clinical Importance and Epidemiology of Quinolone Resistance", Infection and Chemotherapy, 46(4), pp.226~238 (2014), 대한감염학회[DOI]
- Dalhoff A, "Resistance surveillance studies : a multifaceted problem--the fluoroquinolone example", Infection, 40, pp.239~262 (2012)
- Gaynes R, "National Nosocomial Infections Surveillance System. Overview of nosocomial infections caused by gram-negative bacilli", Clin Infect Dis, 41, pp.848~854 (2005)
- Wisplinghoff H, "Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study", Clin Infect Dis, 39, pp.309~317 (2004)
- Vila J, "Mutation in the gyrA gene of quinolone-resistant clinical isolates of Acinetobacter baumannii", Antimicrob Agents Chemother, 39, pp.1201~1203 (1995)
- Vila J, "Quinolone-resistance mutations in the topoisomerase IV parC gene of Acinetobacter baumannii", J Antimicrob Chemother, 39, pp.757~762 (1997)
- Wisplinghoff H, "Mutations in gyrA and parC associated with resistance to fluoroquinolones in epidemiologically defined clinical strains of Acinetobacter baumannii", J Antimicrob Chemother, 51, pp.177~180 (2003)
- Coyne S, "Efflux-mediated antibiotic resistance in Acinetobacter spp", Antimicrob Agents Chemother, 55, pp.947~953 (2011)
- Correia S, "Mechanisms of quinolone action and resistance : where do we stand", J Med Microbiol, 66, pp.551~559 (2017)
- Valentine SC, "Phenotypic and molecular characterization of Acinetobacter baumannii clinical isolates from nosocomial outbreaks in Los Angeles County, California", J Clin Microbiol, 46, pp.2499~2507 (2008)
- Ruiz J, "Mechanisms of resistance to quinolones: target alterations, decreased accumulation and DNA gyrase protection", J Antimicrob Chemother, 51, pp.1109~1117 (2003)
- Hamouda A, "Novel gyrA and parC point mutations in two strains of Acinetobacter baumannii resistant to ciprofloxacin", J Antimicrob Chemother, 54, pp.695~696 (2004)
- Nakano R, "Rapid assay for detecting gyrA and parC mutations associated with fluoroquinolone resistance in Enterobacteriaceae", J Microbiol Methods, 94, pp.213~216 (2013)
- Endo S, "Molecular epidemiology of carbapenem-non-susceptible Acinetobacter baumannii in Japan", J Antimicrob Chemother, 67, pp.1623~1626 (2012)
- Mu X, "Loop-mediated isothermal amplification: Rapid and sensitive detection of the antibiotic resistance gene ISAba1-blaOXA-51-like in Acinetobacter baumannii", J Microbiol Methods, 121, pp.36~40 (2016)
- La Scola B, "Sequencing of the rpoB gene and flanking spacers for molecular identification of Acinetobacter species", J Clin Microbiol, 44, pp.827~832 (2006)
- "Ethical Guidelines for Medical and Health Research Involving Human Subjects"[URL]
- CLSI, "Performance standards for antimicrobial susceptibility testing" (2012), Clinical and Laboratory Standards Institute
- Pournaras S, "Outbreak of multiple clones of imipenem-resistant Acinetobacter baumannii isolates expressing OXA-58 carbapenemase in an intensive care unit", J Antimicrob Chemother, 57, pp.557~561 (2006)
- Hujer KM, "Rapid determination of quinolone resistance in Acinetobacter spp", J Clin Microbiol, 47, pp.1436~1442 (2009)
- Haliassos A, "Modification of enzymatically amplified DNA for the detection of point mutations", Nucleic Acids Res, 17, pp.3606~ (1989)
- Deccache Y, "Development of a pyrosequencing assay for rapid assessment of quinolone resistance in Acinetobacter baumannii isolates", J Microbiol Methods, 86, pp.115~118 (2011)